-year patency for Dacron grafts was 64% (95% confidence interval [C.I.] 55-74%) and for PTFE grafts 61% (C.I. 49-72%). The corresponding 3-year secondary patency was 81% (C.I. 73-89%) and 75% (C.I. 65-86%) respectively, the limb salvage rate 90% (C.I. 84-96%) and 91% (C.I. 84-97%). Upon multivariate analysis below-knee anastomosis was the principal independent predictor of primary graft failure (risk ratio 1.7 [C.I. 1.05-2.8]), impaired secondary patency was associated with infragenicular bypass (risk ratio 3.3 [C.I. 1.8-6.3
Introduction
the surgeon considered a prosthetic graft to be the most appropriate choice. The protocol was in acThere is broad consensus that autologous vein results cordance with the declaration of Helsinki and was in superior long-term patency of infragenicular by-approved by the ethical committee of the University pass.
1,2 However, if autologous vein is not available, of Heidelberg. The following centres contributed to PTFE (Polytetrafluoroethylene) has been the most pop-this study: Chirurgische Universitätsklinik Heidelberg, ular choice.
3-6 However, the preference for PTFE over Universitätsklinikum Mannheim, Josefskrankenhaus Dacron is not evidence based. 7, 8 This trial was planned Heidelberg, Diakonissenkrankenhaus Karslruhe, at a time when no conclusive evidence was available Allgemeines Krankenhaus Hamburg-Altona, Alfriedto justify the preferential use of PTFE grafts.
Exclusion criteria
type of anastomosis (end-to-end vs end-to-side) was left to the choice of the surgeon. Only three of the • Infections at operation sites; patients with below-knee bypass received a distal vein • Emergency surgery for acute ischaemia;
cuff.
• Distal anastomosis below the origin of the anterior tibial artery; Concomitant therapy • Composite grafts or jump grafts;
Any type of pre-or intraoperative inflow re-• No preoperative angiography available sufficient to construction or perioperative minor amputations for judge distal run-off; gangrene were allowed but nevertheless recorded. All • Previous inclusion in this study either for a contra-patients were treated with heparin perioperatively lateral bypass or an earlier ipsilateral one (sim-(dosage and type of administration not standardised). ultaneous bilateral grafts could be included just with Upon discharge the patients were required to receive one side); either anti-platelet drugs, heparin or coumadin. • Concomitant diseases expected to limit life expectancy to below 3 years at the time of ran-Primary end-point domisation; Any occlusion of the graft occurring after the patient • No informed consent to randomisation or un-left the operating theatre, i.e. primary patency was likelihood of regular follow-up (e.g. due to serious chosen as the primary outcome measure. This was doubts regarding compliance); used in the sense of unassisted primary patency,
2
• Contraindications to all types of anticoagulants peri-i.e. in those cases where impeding graft occlusion operatively (upon discharge the patients were re-necessitated reinterventions, the primary end-point quired to receive either anti-platelet drugs, heparin was reached at this moment. In case of graft occlusion or coumadin); later withdrawal of anticoagulants outside medical supervision the time point of marked for any reasons was recorded but was not considered increase in pain or reduction in pain-free walking violation of the protocol; distance was considered as time of graft occlusion. In • Availability of suitable autologous vein (for infra-case of asymptomatic occlusion the half-time between genicular bypass only). Criteria for suitability of the two follow-up visits was considered. Duplex scan saphenous vein were not predetermined. and/or angiography were performed in any case of clinical deterioration and/or clinical suspicion of graft Randomisation occlusion. Patients were randomised to either treatment arm intraoperatively by sealed envelopes. The order of Secondary end-points assignment had been generated by random digits from Secondary patency and limb salvage (avoiding major a statistical software package (SAS). The envelopes amputation) were chosen as secondary outcome measwere drawn only following surgical exposure of the ures. sites of proximal and distal anastomosis and judging the vessels appropriate for the intended reconstruction. Sample size Randomisation was stratified both for participating The study was designed to detect a difference between hospital and for the site of distal anastomosis (supra-50% and 70% primary patency after 3 years with = genicular vs infragenicular).
0.05 and =0.2. The expectation of a 20% difference came out of a retrospective analysis within the deMaterials partmental records of the senior author demonstrating Patients assigned to the "DACRON" group received an advantage of this magnitude in favour of Dacron unsealed knitted polyester velour grafts ("Microvel" grafts. For actuarial analysis by two-sided log-rank Meadox Company, Ratingen/Germany, taken over by test this would require 193 patients for analysis.
10
Boston Scientific Vascular during the course of the Assuming a drop-out rate of 5% we planned to ranstudy); for infragenicular anastomosis spiral-enforced domise a total of 203 patients. A planned interim protheses were applied. Dacron protheses were sealed analysis was performed after randomisation of 100 by autologous blood intraoperatively. Patients as-patients showing no conclusive evidence for early signed to the "PTFE" group received "Thin wall TW" termination of the study according to preset criteria. grafts above knee and "Ring removable RTW" grafts infragenicular (W.L. Gore Associates, Putzbrunn/Ger-Follow-up Patency of graft upon primary discharge had to be many). Both type and size of suture materials as well as the diameter of the prosthesis (6 or 8 mm) or the proven by either angiography or duplex sonography. (range: 6-72 months) was reached. A total of 141 patients received a supragenicular bypass, 53 an infragenicular bypass. Table 1 lists the distribution of imPlanned follow-up visits were scheduled to take place portant covariables among the treatment arms. after 3 and 6 months as well as 1, 2, 3, 4, and 5 years postoperatively. Extraordinary visits were performed in case of any clinical or subjective deterioration.
Primary patency Figure 1 shows the data on overall unassisted primary patency of the grafts. As it is easily visible there was actually no difference between the two treatment arms Statistical analysis (log-rank test p=0.89): the actuarial 3-year patency for Dacron grafts was 64% (95% confidence interval [CI] Differences were considered significant at p<0.05 (twosided). Patency and limb salvage data were estimated 55-74%) and for PTFE grafts 61% (C.I. 49-72%). Univariate analysis of the potentially important coby the Kaplan-Meier method comparing both treatment arms by log-rank test. Multivariate analysis was variables revealed a significant impact on primary patency for infragenicular bypass (p=0.03, log-rank performed by the Cox proportional-hazards model with stepwise variable selection (p<0.05 for entry and test), poor run-off (p=0.046), and the presence of critical limb ischaemia (p=0.02). In multivariate anaremoval of variables from the model). The covariables listed in Table 1 were included in the multivariate lysis the only significant variable contributing to primary patency was the site of distal anastomosis where analysis provided a p-value below 0.25 was reached on univariate analysis. The type of graft was always infragenicular bypass resulted in an increased risk ratio of 1.7 (C.I. 1.05-2.8, p=0.03). Upon subgroup included in multivariate calculations. Calculations were performed by the SAS statistical software pack-analysis for this parameter it was obvious that there was a markedly worse outcome for infragenicular age (SAS Institute, Cary, NC, U.S.A.). (Fig. 1) was no longer visible upon looking at secondary patency leading to almost identical secondary patency rates for both types of graft. The actuarial 3-year secondary patency for Dacron grafts was 81% (C.I. 73-89%) and for PTFE grafts 75% (C.I. 65-86%). Univariate analysis of the covariables showed a significantly decreased secondary patency for infragenicular bypass (p=0.0001), distal gangrene (p= 0.005), as well as critical limb ischaemia (p=0.002). In addition, bypasses performed in centre A had de- that beyond 2.5 years postoperatively we did not observe any occlusion in above-knee bypasses.
success (26 Dacron grafts, 16 PTFE grafts). The increased number of early occlusions in Dacron grafts
1.8-6.3] p=0.0002) and distal gangrene/Fontaine stage IV disease (risk ratio 2.0 [C.I. 1.01-3.8] p=0.048) were independently predictive of impaired secondary patency.
Amputation
Limb salvage was successfully achieved in most of the cases. At 3 years postoperatively the rate was 90% (C.I. 84-96%) in the DACRON arm and 91% (C.I. 84-97%) in the PTFE treatment arm (p=0.56). Univariate analysis showed six variables to be associated operation exceeding 3 h (p=0.003), poor run-off index (p=0.007), and operation in centre A (p=0.04). Upon bypass. Differences in primary patency between Da-multivariate analysis three of these remained incron and PTFE for different sites of distal anastomosis dependently associated with major amputations: (Figs 2 and 3) were not statistically significant neither below-knee bypass (risk ratio 4.2 [C.I. 1.8-10.1] p= on univariate nor on multivariate calculations. In 0.001), tissue necrosis/Fontaine stage IV disease (risk supragenicular bypasses the 3-year patency for Dacron ratio 3.9 [C.I. 1.6-9.1] p=0.002), as well as a poor grafts was 70% (C.I. 60-81%) and for PTFE grafts 62% run-off index (risk ratio 3.4 [C.I. 1.1-10.1] p=0.03) (C.I. 50-75%) whereas in infragenicular bypasses the decreased the chance of limb salvage. numbers were 46% (C.I. 26-66%) and 60% (C.I. 37-82%) for Dacron and PTFE respectively. When the multivariate analysis was repeated with stratification for the site of distal anastomosis, poor run-off (index of Discussion 4 or above) was predictive of worse outcome (risk ratio 1.7, C.I. 1.02-2.7, p=0.04).
Due to the shortcomings of retrospective data 11 the present results will be compared only with previous randomised trial data. An early prospective study which was partly randomised compared 36 PTFE with Secondary patency 10 composite Dacron-vein below-knee bypasses; the authors reached the conclusion that further use of In 67 grafts a primary occlusive event was observed. Of these 42 could be recanalised -at least with temporary Dacron-vein composites was not justified. 12 ported recently with a prolonged follow-up. 15 In 240 will reach the same level of evidence within shorter above-knee grafts no difference in patency could be time. detected between PTFE and Dacron grafts. Lastly, a randomised trial from Australia with a total of 108 patients (75 above-knee and 33 below-knee grafts) confirmed that there is no difference in primary and Acknowledgements secondary patency between PTFE and Dacron grafts in femoro-popliteal position. 16 Unlike the present study pregnated and unimpregnated grafts except easier intraoperative handling of impregnated and lower costs for unsealed Dacron grafts.
In the present study, with its limited number of References patients, there is still a risk of a type II error, i.e. smaller differences might have been overlooked. Although a
